ストックスクリーナーアプリを入手
1,196.03
0.86%
10.16
プレマーケット:
1199.68
3.65
+0.31%
前日終値:
$1,185.87
開ける：
$1194.35
24時間の取引高:
1.98M
Relative Volume:
0.63
時価総額：
$1.07T
収益：
$72.25B
当期純損益:
$25.28B
株価収益率:
43.05
EPS:
27.781
ネットキャッシュフロー:
$10.37B
1週間 パフォーマンス:
+1.43%
1か月 パフォーマンス:
+7.05%
6か月 パフォーマンス:
+12.38%
1年 パフォーマンス:
+48.50%
1日の値動き範囲:
$1,187.50
$1,206.94
1週間の範囲:
$1,139.00
$1,206.94
52週間の値動き範囲:
$623.78
$1,249.45
Lilly Eli Co Stock (LLY) Company Profile
Compare LLY vs JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,196.03 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
263.40 | 634.77B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
259.36 | 458.24B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
131.07 | 323.72B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
155.01 | 294.63B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-17 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2026-02-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2026-02-20 | 開始されました | Barclays | Overweight |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-12-16 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | 繰り返されました | BofA Securities | Buy |
| 2025-12-15 | 繰り返されました | Goldman | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-11-10 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | 繰り返されました | BMO Capital Markets | Outperform |
| 2025-10-14 | アップグレード | Erste Group | Hold → Buy |
| 2025-09-17 | ダウングレード | Berenberg | Buy → Hold |
| 2025-08-27 | アップグレード | HSBC Securities | Reduce → Hold |
| 2025-08-18 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | ダウングレード | Erste Group | Buy → Hold |
| 2025-04-28 | ダウングレード | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-09-13 | 再開されました | Citigroup | Buy |
| 2024-08-12 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-02-21 | ダウングレード | DZ Bank | Buy → Hold |
| 2024-02-16 | 繰り返されました | Morgan Stanley | Overweight |
| 2023-12-21 | ダウングレード | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-10-20 | 再開されました | UBS | Buy |
| 2023-08-09 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-26 | 繰り返されました | Citigroup | Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-05-24 | 繰り返されました | BofA Securities | Buy |
| 2023-05-24 | 繰り返されました | UBS | Buy |
| 2023-03-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-15 | ダウングレード | Societe Generale | Hold → Sell |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-09-22 | アップグレード | UBS | Neutral → Buy |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2022-03-10 | 開始されました | Daiwa Securities | Outperform |
| 2022-01-21 | アップグレード | DZ Bank | Hold → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-16 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-12-16 | 繰り返されました | BofA Securities | Buy |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-10-11 | アップグレード | Berenberg | Hold → Buy |
| 2021-09-29 | アップグレード | Citigroup | Neutral → Buy |
| 2021-08-05 | アップグレード | DZ Bank | Hold → Buy |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-06-24 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2021-01-19 | アップグレード | Mizuho | Neutral → Buy |
| 2020-12-10 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-09-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-04-21 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2019-12-18 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-05-28 | 開始されました | Goldman | Buy |
| 2019-04-24 | アップグレード | Edward Jones | Hold → Buy |
| 2019-04-11 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-03-12 | 開始されました | JP Morgan | Overweight |
| 2019-01-23 | 開始されました | UBS | Buy |
| 2018-11-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2018-10-31 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2018-10-01 | 繰り返されました | SunTrust | Buy |
| 2018-09-26 | 再開されました | JP Morgan | Overweight |
すべてを表示
Lilly Eli Co (LLY) 最新ニュース
Eli Lilly (NYSE:LLY) climbs into the spotlight as weight-loss drug demand runs hot - Kalkine Media
Eli Lilly delays FDA filing for next-generation weight-loss drug retatrutide - NewsNation
Caxton Associates LLP Has $1.40 Million Stock Position in Eli Lilly and Company $LLY - InsuranceNewsNet
Is the VanEck Pharmaceutical ETF or State Street Health Care ETF the Better Buy for Your Portfolio? - The Motley Fool
Eli Lilly (NYSE:LLY): High-Growth Stock with Strong Technical and Fundamental Momentum - ChartMill
Jim Cramer Wants Novo Nordisk A/S (NYSE:NVO) To Compete With Eli Lilly In The Market & Not The Courts - Yahoo Finance
Eli Lilly-Backed Scribe Therapeutics Jumps 67% After Upsized IPO - Bloomberg.com
Novo Asks NJ Judge To Stop Lilly's 'Deceptive' GLP-1 Ads - Law360
Novo Nordisk Sues Eli Lilly Over Misleading Ads - Intellectia AI
Novo Nordisk (CPSE:NOVO B) Sues Eli Lilly Over GLP 1 Drug Advertising - Yahoo Finance
Novo Nordisk seeks preliminary injunction days after suing Eli Lilly - MobiHealthNews
Novo Nordisk Seeks Pause on Eli Lilly’s Weight Loss Drug Ads - Bloomberg Law News
Novo asks court to block Lilly ads; Merck strikes HIV PrEP deal - Endpoints News
Novo Nordisk pursues preliminary injunction to block Eli Lilly weight-loss drug ads - PharmaLive
Novo Nordisk seeks injunction to block Eli Lilly weight loss drug ads - Yahoo Finance
Novo Nordisk Reportedly Escalates Legal Battle Against Eli Lilly – Even As Analysts See LLY Leading The GLP-1 Race - Stocktwits
Novo Nordisk Seeks Injunction Against Eli Lilly in Dispute Over Weight-Loss Ads - Yahoo Finance
The legal battle continues – Novo now seeks a temporary ban on Eli Lilly's advertisements - medwatch.com
This Billionaire Made $360 Million Selling His Psychedelic Company To Eli Lilly - Forbes
Novo Nordisk seeks court order to halt Eli Lilly drug ads - Investing.com Nigeria
Novo Nordisk seeks preliminary injunction against Lilly weight-loss ads - Yahoo Finance UK
LLY|Eli Lilly and Co|Price:1196.030|Chg%:+10.490 - TradingKey
Novo Investors: Lawsuit against Eli Lilly is apt - medwatch.com
Eli Lilly stock holds after 2025 revenue and profit growth - Ad-hoc-news.de
Novo Nordisk’s fight against Eli Lilly has gone legal: A top lawyer evaluates the case - Business Post
Eli Lilly and Company Price Today | XLLY Live Price, Chart & Market Cap - OKX
Eli Lilly Reports Positive Results from Two Phase III Trials | PharmExec - Pharmaceutical Executive
Novo Nordisk Sues Eli Lilly Over Zepbound and Mounjaro Advertising Claims - Law Commentary
Lilly's Next-Generation Obesity Shot Clears Another Hurdle - Yahoo Finance UK
Eli Lilly (NYSE:LLY) Shapes the Healthcare Earnings Narrative - Kalkine Media
Lilly Targets Early 2027 Filing for Next Obesity Drug - Yahoo Finance
Eli Lilly's Retatrutide Clears Two More Trials Ahead of 2027 Filing - Yahoo Finance
Lilly, with new data, to seek FDA approval of obesity drug retatrutide - BioPharma Dive
Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application - Reuters
Lilly to file for next-gen obesity drug approval in early 2027 - Yahoo Finance
Eli Lilly (NYSE:LLY) Growth & Technical Setup Signal A Key Market Test - Kalkine Media
Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 data - BioSpace
Lilly Endowment reports 90.4M Eli Lilly (LLY) shares, a 9.6% stake - Stock Titan
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q2 Results? - Yahoo Finance UK
Eli Lilly’s Anticipated Weight Loss Drug Helped People Lose 56 Pounds On Average - Forbes
Eli Lilly Delay Puts Madrigal Stock In Focus For Obesity Drug Investors - simplywall.st
Novo Nordisk Lawsuit Against Eli Lilly: Wegovy Maker Alleges Misleading Zepbound, Mounjaro Ads - Stocktwits
Eli Lilly’s Next-Generation Weight-Loss Shot Clears Another Hurdle - Bloomberg.com
Eli Lilly (LLY) Advances Next-Gen Weight-Loss Therapy with Promi - GuruFocus
Eli Lilly presents positive safety data but postpones weight-loss candidate application - medwatch.com
Eli Lilly to File FDA Approval for Retatrutide in 2027 After Five Positive Phase 3 Trials - MLQ.ai
Eli Lilly and Co.'s next-generation obesity drug has had its market application delayed until 2027. - 富途牛牛
Eli Lilly (LLY) Reports Positive Phase 3 Trial Results for Retat - GuruFocus
Eli Lilly to seek obesity drug approval in Q1 2027 - Breakingthenews.net
Eli Lilly to seek approval for powerful new obe... - Pluang
Lilly’s retatrutide meets endpoints in two phase 3 obesity trials - Investing.com
Lilly Eli Co (LLY) 財務データ
収益
当期純利益
現金流量
EPS
1.59%
0.72%
大文字化:
|
ボリューム (24 時間):